Page last updated: 2024-12-10
norbixin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
norbixin: an annatto compound; RN given refers to all-trans-norbixin (beta-norbixin); 9-cis-norbixin is alpha-norbixin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5281249 |
| CHEMBL ID | 1602127 |
| CHEBI ID | 7623 |
| SCHEMBL ID | 42367 |
| SCHEMBL ID | 23576251 |
| MeSH ID | M0261929 |
Synonyms (30)
| Synonym |
|---|
| einecs 208-810-8 |
| 6,6'-diapo-psi,psi-carotenedioic acid |
| 9'-cis-diapo-omega,omega-carotinsaeure |
| 9'-cis-6,6'-diapocaroten-6,6'-disaeure |
| e 160b |
| 2,4,6,8,10,12,14,16,18-eicosanonaenedioic acid, 4,8,13,17-tetramethyl- |
| LMPR01070209 |
| NCGC00091554-01 |
| 542-40-5 |
| norbixin |
| C08608 |
| trans-norbixin |
| (2e,4e,6e,8e,10e,12e,14e,16e,18e)-4,8,13,17-tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioic acid |
| e8m59e17ai , |
| unii-e8m59e17ai |
| .beta.-norbixin |
| norbixin [mart.] |
| all-trans norbixin |
| (all-e)-4,8,13,17-tetramethyl-2,4,6,8,10,12,14,16,18-eicosanonaenedioic acid |
| .beta.-norbixin [mi] |
| SCHEMBL42367 |
| CHEMBL1602127 |
| CHEBI:7623 , |
| all-trans-norbixin |
| DTXSID20274024 |
| ZVKOASAVGLETCT-UOGKPENDSA-N |
| DB15201 |
| Q1997371 |
| norbixin(p) |
| SCHEMBL23576251 |
Research Excerpts
Overview
Norbixin is an unusual dicarboxylic water-soluble carotenoid. It is present as a component in the pericarp of the seeds of Bixa orellana L.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Norbixin (NBIX) is a carotenoid with antioxidant potential largely used in the food industry." | ( Prooxidant activity of norbixin in model of acute gastric ulcer induced by ethanol in rats. Araldi, IC; Augusti, PR; Bauermann, Lde F; da Rocha, MP; de Freitas, RB; Emanuelli, T; Quatrin, A; Rovani, BT; Somacal, S, 2016) | 1.47 |
| "Norbixin is an unusual dicarboxylic water-soluble carotenoid present as a component in the pericarp of the seeds of Bixa orellana L." | ( Antigenotoxic and antimutagenic potential of an annatto pigment (norbixin) against oxidative stress. Asad, LM; Asad, NR; Felzenszwalb, I; Júnior, AC; Kovary, K; Oliveira, EB, 2005) | 1.29 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with norbixin-based PHB membranes reduces the inflammatory response, increases fibroblast proliferation, and improves collagen production in the tendon repair region, especially between days 7 and 14." | ( Effect of norbixin-based poly(hydroxybutyrate) membranes on the tendon repair process after tenotomy in rats. Carvalho, LFM; Ferreira, DCL; Figueredo-Silva, J; Fonseca, KM; Maia Filho, ALM; Nascimento, LDES; Nicolau, RA; Santos, JZLV; Sousa, RC; Viana, VGF, 2020) | 1.31 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " There were no treatment-related adverse effects on body weight, food and water consumption, ophthalmology and hematology data." | ( A thirteen-week oral toxicity study of annatto extract (norbixin), a natural food color extracted from the seed coat of annatto (Bixa orellana L.), in Sprague-Dawley rats. Aoki, H; Hagiwara, A; Ichihara, T; Imai, N; Koda, T; Nakamura, M; Sano, M; Shirai, T; Tamano, S; Yasuhara, K, 2003) | 0.57 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Here, the in vitro bioaccessibility and potential bioavailability of norbixin, the abundant 24-carbon carotenoid in annatto, were investigated." | ( Digestive stability and transport of norbixin, a 24-carbon carotenoid, across monolayers of Caco-2 cells. Failla, ML; Huo, T; Polar-Cabrera, K; Schwartz, SJ, 2010) | 0.87 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| diterpenoid | Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (14)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 2.5119 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 2.8184 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 25.1189 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 25.1189 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 11.2202 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 19.9526 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 25.1189 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 31.6228 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 44.6684 | 0.0010 | 19.4141 | 70.9645 | AID588536 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 25.1189 | 0.0100 | 39.5371 | 1,122.0200 | AID588545 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 45.3292 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 31.6228 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 31.6228 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 1.3333 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (34)
Molecular Functions (17)
Ceullar Components (11)
Research
Studies (68)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.94) | 18.2507 |
| 2000's | 15 (22.06) | 29.6817 |
| 2010's | 36 (52.94) | 24.3611 |
| 2020's | 15 (22.06) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 57.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (57.31) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (2.94%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 66 (97.06%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||